Vincent Yi-Fong Su1,2,3, Chia-Jen Liu3,4,5, Yuh-Min Chen3,6, Teh-Ying Chou2,3,7, Tzeng-Ji Chen3,8, Sang-Hue Yen3,9,10, Tzeon-Jye Chiou3,11,12, Jin-Hwang Liu3,4, Yu-Wen Hu13,14,15. 1. Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 2. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. 4. Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Institute of Public Health, National Yang-Ming University, Taipei, Taiwan. 6. Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan. 7. Molecular Pathology, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 8. Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 9. Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan. 10. Department of Biomedical Imaging and Radiological Sciences, School of Medicine, National Yang-Ming University, Taipei, Taiwan. 11. Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 12. National Defense Medical Center, Taipei, Taiwan. 13. Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. mimicx@gmail.com. 14. Institute of Public Health, National Yang-Ming University, Taipei, Taiwan. mimicx@gmail.com. 15. Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan. mimicx@gmail.com.
Abstract
BACKGROUND: Currently, no large study addressing the relationship between lung cancer patients with different therapies and second primary malignancies (SPMs) is available. METHODS: Using the Taiwan National Health Insurance Research Database, we conducted a population-based cohort study. Patients with newly diagnosed lung cancer between 1997 and 2005 were enrolled and followed up until Dec. 31, 2011. The endpoint of the study was SPM occurrence. Standardized incidence ratios (SIRs) of cancers were calculated to compare the cancer incidence of the study cohort to that of the general population. RESULTS: We identified 52,639 patients with lung cancer and excluded 34,267 patients who had expired within one year after diagnosis. The study included 18,372 subjects with a median follow-up period of 2.24 years. 590 patients developed an SPM. The overall cancer risk was significantly increased (SIR 1.33, 95% confidence interval [CI]: 1.22-1.44, p < 0.001), and there was a significant increase in the incidences of head and neck (SIR 1.60, 95% CI 1.21-2.07, p = 0.001), bone and soft tissue (SIR 2.65, 95% CI 1.27-4.87, p = 0.011), genitourinary (SIR 1.50, 95% CI 1.27-1.76, p < 0.001), and thyroid (SIR 3.85, 95% CI 2.28-6.08, p < 0.001) cancers. Importantly, after multivariate adjustment, the use of tyrosine kinase inhibitors (TKIs) statistically significantly reduced SPM incidence (HR, 0.41; 95% CI, 0.21-0.79; p = 0.008). CONCLUSIONS: Our study indicates that lung cancer may be a risk factor for SPM. TKI use was associated with a significantly lower risk of SPM development. However, because patients with epidermal growth factor receptor mutant lung adenocarcinoma (associated with non-smokers) tend to receive TKI treatment, they might have fewer smoking-related SPMs.
BACKGROUND: Currently, no large study addressing the relationship between lung cancerpatients with different therapies and second primary malignancies (SPMs) is available. METHODS: Using the Taiwan National Health Insurance Research Database, we conducted a population-based cohort study. Patients with newly diagnosed lung cancer between 1997 and 2005 were enrolled and followed up until Dec. 31, 2011. The endpoint of the study was SPM occurrence. Standardized incidence ratios (SIRs) of cancers were calculated to compare the cancer incidence of the study cohort to that of the general population. RESULTS: We identified 52,639 patients with lung cancer and excluded 34,267 patients who had expired within one year after diagnosis. The study included 18,372 subjects with a median follow-up period of 2.24 years. 590 patients developed an SPM. The overall cancer risk was significantly increased (SIR 1.33, 95% confidence interval [CI]: 1.22-1.44, p < 0.001), and there was a significant increase in the incidences of head and neck (SIR 1.60, 95% CI 1.21-2.07, p = 0.001), bone and soft tissue (SIR 2.65, 95% CI 1.27-4.87, p = 0.011), genitourinary (SIR 1.50, 95% CI 1.27-1.76, p < 0.001), and thyroid (SIR 3.85, 95% CI 2.28-6.08, p < 0.001) cancers. Importantly, after multivariate adjustment, the use of tyrosine kinase inhibitors (TKIs) statistically significantly reduced SPM incidence (HR, 0.41; 95% CI, 0.21-0.79; p = 0.008). CONCLUSIONS: Our study indicates that lung cancer may be a risk factor for SPM. TKI use was associated with a significantly lower risk of SPM development. However, because patients with epidermal growth factor receptor mutant lung adenocarcinoma (associated with non-smokers) tend to receive TKI treatment, they might have fewer smoking-related SPMs.
Authors: B E Johnson; R I Linnoila; J P Williams; D J Venzon; P Okunieff; G B Anderson; G E Richardson Journal: J Clin Oncol Date: 1995-01 Impact factor: 44.544
Authors: Laurelle van Tilburg; Steffi E M van de Ven; Manon C W Spaander; Laurens A van Kleef; Robin Cornelissen; Marco J Bruno; Arjun D Koch Journal: J Cancer Res Clin Oncol Date: 2022-06-23 Impact factor: 4.553
Authors: Matthew E Barclay; Georgios Lyratzopoulos; Fiona M Walter; Sarah Jefferies; Michael D Peake; Robert C Rintoul Journal: Thorax Date: 2019-02-18 Impact factor: 9.139